The Food and Drug Administration (FDA) has further expanded the U.S. indications of Novo Nordisk’s (NVO) popular weight loss ...

Novo Nordisk said on Friday the U.S. Food and Drug Administration has granted accelerated approval for its weight-loss drug ...

Novo Nordisk’s obesity drug Wegovy was cleared by U.S. regulators to treat an increasingly common liver disease, MASH.

MASLD has become the most common chronic liver disease worldwide. The authors review the features of the disease as well as ...

Novo Nordisk today announced that the US Food and Drug Administration (FDA) has approved an additional indication for Wegovy® ...

Plainsboro: Novo Nordisk has received approval from the US Food and Drug Administration (FDA) for a new indication for Wegovy (semaglutide) injection 2.4 mg, making it the first and ...

Wegovy® (semaglutide) injection 2.4 mg is now indicated to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver ...

I am reversing my rating on Akero Therapeutics stock from Buy to Sell due to valuation concerns and a long-ish wait for ...